These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34247623)

  • 1. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance.
    Giusca S; Steen H; Montenbruck M; Patel AR; Pieske B; Erley J; Kelle S; Korosoglou G
    J Cardiovasc Magn Reson; 2021 Jul; 23(1):92. PubMed ID: 34247623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Feature Tracking and Late Gadolinium Enhancement for Identification Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease.
    Liu S; Li Y; Zhao Y; Wang X; Wu Z; Gu X; Xu B; Li Y; Tian J; Cui J; Wang G; Yu B
    Front Cardiovasc Med; 2022; 9():865615. PubMed ID: 35647085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-parametric non-contrast cardiac magnetic resonance for the differentiation between cardiac amyloidosis and hypertrophic cardiomyopathy.
    Steen H; Montenbruck M; Kallifatidis A; André F; Frey N; Kelle S; Korosoglou G
    Clin Res Cardiol; 2024 Mar; 113(3):469-480. PubMed ID: 38095711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy.
    Lavall D; Vosshage NH; Geßner R; Stöbe S; Ebel S; Denecke T; Hagendorff A; Laufs U
    Clin Res Cardiol; 2023 Mar; 112(3):334-342. PubMed ID: 35355115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis.
    Steen H; Giusca S; Montenbruck M; Patel AR; Pieske B; Florian A; Erley J; Kelle S; Korosoglou G
    J Cardiovasc Magn Reson; 2021 Apr; 23(1):45. PubMed ID: 33823860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy.
    Neisius U; Myerson L; Fahmy AS; Nakamori S; El-Rewaidy H; Joshi G; Duan C; Manning WJ; Nezafat R
    PLoS One; 2019; 14(8):e0221061. PubMed ID: 31433823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics.
    Williams LK; Forero JF; Popovic ZB; Phelan D; Delgado D; Rakowski H; Wintersperger BJ; Thavendiranathan P
    J Cardiovasc Magn Reson; 2017 Aug; 19(1):61. PubMed ID: 28784140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy.
    Zhi Y; Gui FD; Xue M; Long YT; Miao W; Yi Y; Gao LC; Bing F; Pan SY
    BMC Cardiovasc Disord; 2024 Apr; 24(1):203. PubMed ID: 38594610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrated Algorithm for Differentiating Hypertrophic Cardiomyopathy From Hypertensive Heart Disease.
    Kong LC; Wu LM; Wang Z; Liu C; He B
    J Magn Reson Imaging; 2023 Oct; 58(4):1084-1097. PubMed ID: 36688928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The association between cardiac mr feature tracking strain and myocardial late gadolinium enhancement in patients with hypertrophic cardiomyopathy].
    Ozden O; Unlu S; Kilic DI; Sherif SA; Opan S; Kemal HS; Ozmen E; Tuner H; Bingol G; Barutcu A; Nasifov M; Bakan S; Goktekin O
    Kardiologiia; 2023 Feb; 63(2):52-58. PubMed ID: 36880144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
    Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
    Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy.
    Arenja N; Fritz T; Andre F; Riffel JH; Aus dem Siepen F; Ochs M; Paffhausen J; Hegenbart U; Schönland S; Müller-Hennessen M; Giannitsis E; Kristen AV; Katus HA; Friedrich MG; Buss SJ
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1414-1422. PubMed ID: 28165128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.
    Takeda M; Amano Y; Tachi M; Tani H; Mizuno K; Kumita S
    Jpn J Radiol; 2013 Oct; 31(10):693-700. PubMed ID: 23996116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac MRI findings to differentiate athlete's heart from hypertrophic (HCM), arrhythmogenic right ventricular (ARVC) and dilated (DCM) cardiomyopathy.
    Kübler J; Burgstahler C; Brendel JM; Gassenmaier S; Hagen F; Klingel K; Olthof SC; Blume K; Wolfarth B; Mueller KAL; Greulich S; Krumm P
    Int J Cardiovasc Imaging; 2021 Aug; 37(8):2501-2515. PubMed ID: 34019206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].
    Cui Q; Yu J; Shen W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1538-1541. PubMed ID: 32029045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease.
    Liang L; Wang X; Yu Y; Zhang Y; Liu J; Chen M; Zhang L; Jiang T
    Int J Gen Med; 2022; 15():4163-4173. PubMed ID: 35465304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.
    Xu J; Zhuang B; Sirajuddin A; Li S; Huang J; Yin G; Song L; Jiang Y; Zhao S; Lu M
    Radiology; 2020 Feb; 294(2):275-286. PubMed ID: 31769741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac magnetic resonance T2 mapping and feature tracking in athlete's heart and HCM.
    Gastl M; Lachmann V; Christidi A; Janzarik N; Veulemans V; Haberkorn S; Holzbach L; Jacoby C; Schnackenburg B; Berrisch-Rahmel S; Zeus T; Kelm M; Bönner F
    Eur Radiol; 2021 May; 31(5):2768-2777. PubMed ID: 33063183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.